Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 04 May 2016 | By Zachary Brennan
The draft guidance on the special protocol assessment (SPA) process is an update on guidance from 2002 and delves into the meetings between pharmaceutical or biotech sponsors and the US Food and Drug Administration (FDA) to discuss plans for clinical trials.
Under the hopes that the SPA process will improve the quality of clinical trials, FDA has made significant changes from 2002 guidance, including:
SPA provides for the evaluation of protocols for trials that have not been initiated, meaning the existence of an SPA agreement does not guarantee that FDA will accept a new drug application (NDA) or biologics license application (BLA), or that the trial results will be adequate to support approval.
The following protocols are eligible for an SPA request:
Protocols are reviewed by FDA “for the adequacy and acceptability of critical elements of overall protocol design and analysis” and the SPA process allows time for FDA to respond to relevant questions posed by the sponsor.
The agency says it understands that the efficiency of its review of the SPA submission, the completeness of FDA’s answers to sponsor questions, and the quality of the future NDA or BLA may be improved by holding such a meeting before a submission.
“For example, an SPA agreement for a protocol might communicate to the sponsor that FDA agrees with the proposed primary endpoint or the sample size estimate, but might not include a detailed review of the case report form; it might address the adequacy of and final timing of a radiographic procedure used to measure the primary endpoint, but might not comment on the use of three versus four interim radiographs,” FDA says.
FDA calls on sponsors to make every effort to identify unusual or potentially problematic aspects of the protocol and submit specific questions in their SPA request.
In addition to offering details on procedures for submitting a request, the content of that request and submission materials, the guidance delves into FDA’s assessment process, which involves determining if a submission is appropriate, how to revise the protocol prior to the meeting and the obligations FDA has in responding to sponsors.
The draft also includes information on the options a sponsor has if FDA does not agree to a meeting, how to initiate a trial without an SPA agreement and how to discuss any such disagreements.
Special Protocol Assessment Guidance for Industry
Tags: SPA, special protocol assessments, clinical trial meetings with FDA
Regulatory Focus newsletters
All the biggest regulatory news and happenings.